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and 3, whereas the production of psoriasin and koebnerisin 
was markedly decreased in keloid-derived cells and keloid 
tissue. Both S100 proteins inhibited the expression of colla-
gens, fibronectin-1, α-smooth-muscle actin and TGF-β by fi-
broblasts. Further, they also suppressed fibroblast prolifera-
tion.  Conclusion: Psoriasin and koebnerisin show antifibrot-
ic effects and may lead to novel preventive and therapeutic 
strategies for fibroproliferative diseases. 
 © 2014 S. Karger AG, Basel 
 Introduction 
 Excess scar formation occurs after dermal injury as a 
result of abnormal wound healing. Both hypertrophic 
scars and keloids are associated with significant morbid-
ity by causing pruritus, pain and/or contractures, which 
significantly affect the patient’s quality of life  [1] . Despite 
the relatively high prevalence of keloids and hypertrophic 
scars in the general population, the molecular mecha-
nisms underlying excessive scar formation are not fully 
understood. Most therapeutic strategies remain unsatis-
factory due to poor knowledge of the complex mecha-
nisms underlying the process of excessive scarring  [2–4] .
 Excessive scar tissue formation results from increased 
fibroblast proliferation and disturbed extracellular ma-
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 Abstract 
 Background/Aims: Keloids result from aberrations in the 
normal wound healing cascade and can lead to pruritus, 
contractures and pain. The underlying mechanisms of exces-
sive scarring are not yet understood, and most therapeutic 
strategies remain unsatisfactory. Psoriasin (S100A7) and 
koebnerisin (S100A15) are released by keratinocytes during 
physiological wound healing. We found S100 production is 
markedly decreased in keloid scar tissue. The disturbed epi-
dermal S100 expression might contribute to keloid forma-
tion; thus, we studied their effect on dermal fibroblasts and 
extracellular matrix (ECM) production.  Methods: S100 pep-
tides, ECM regulation and distribution were analysed in nor-
mal and keloid tissue by quantitative PCR (qPCR), immunob-
lotting and immunofluorescent staining. Isolated dermal fi-
broblasts were incubated with S100 proteins, and the 
regulation of ECM and transforming growth factor (TGF)-β 
was determined using qPCR. Fibroblast proliferation and vi-
ability were determined by the 5-bromo-2’-deoxyuridine as-
say and crystal violet assay.  Results: Keloid tissue featured a 
pronounced expression of ECMs, such as collagen types 1 
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trix (ECM) deposition in the dermis. Keloids and hyper-
trophic scars are densely populated by inflammatory cells 
that release fibrogenic factors, such as transforming 
growth factor-β (TGF-β). This environment leads to in-
creased transcription and translation of collagen I and III, 
fibronectin and laminin, as well as deficient ECM degra-
dation and remodelling  [5] . Recent evidence suggests that 
both the severity of inflammation and the type of immune 
response predispose to excessive scar formation  [5] . De-
velopment of a Th2 response promotes fibrogenesis, 
whereas a Th1 predominance attenuates tissue fibrosis  [6, 
7] . Current research in keloid pathophysiology further 
suggests that epidermal-dermal interactions  [8] and al-
terations of the fibroblast phenotype through several 
(growth) factors and downstream signalling pathways  [9] 
may be involved in excessive scarring.
 Recently, high levels of psoriasin (S100A7) proteins 
have been detected in human wound exudate and granu-
lation tissue  [10] . Immunohistological studies suggest 
that psoriasin is produced by keratinocytes surrounding 
the wound and is released into the wound exudate to in-
hibit bacterial survival  [11] . S100 proteins are effectors of 
calcium-dependent processes and intervene with the 
control of cell cycle, cell growth and cell differentiation as 
well as chemoattractants for inflammatory cells  [12 ,  13] . 
Hence, the expression of S100 proteins has been associ-
ated with epidermal maturation, inflammation and 
wound healing  [14–16] . 
 Koebnerisin (S100A15) protein shares 93% overall 
identity with psoriasin, with differences mainly concern-
ing the deduced N-terminal Ca 2+ -binding site  [17] . Koe-
bnerisin expression is induced in cultured human kera-
tinocytes upon treatment with tumour necrosis factor-α 
and interferon (IFN)-γ, and interleukin-1β, suggesting 
that the pro-inflammatory environment in diseased skin 
contributes to koebnerisin expression in the epidermis. 
A similar regulation pattern through Th1 cytokines has 
been shown for psoriasin with coregulation of both pso-
riasin and koebnerisin in inflammation  [18] . In fact, 
compared with normal skin, both psoriasin and koeb-
nerisin proteins are upregulated in inflamed lesional 
skin, such as in psoriasis or chronic atopic eczema  [18] . 
Since we observed that patients suffering from psoriasis 
rarely develop keloids upon dermal injury (observation 
of the authors), we hypothesized that psoriasin/koeb-
nerisin proteins may have antifibrotic effects. Indeed, 
here, we could demonstrate that epidermal psoriasin and 
koebnerisin alone or in combination have suppressive 
effects on ECM production and fibroblast proliferation 
in vitro. 
 Materials and Methods 
 Patients and Skin Samples 
 Sample acquisition was approved by the local ethical commit-
tee (Faculty of Medicine, Ludwig-Maximilian University, Munich, 
Germany). The study was conducted according to the Declaration 
of Helsinki principles. For all procedures, informed written con-
sent was obtained from the patients. Skin biopsies were taken from 
patients (n = 9) who underwent surgical removal of keloid tissue. 
Gender- and age-matched tissue specimens from patients (n = 9) 
with no history of excessive scarring served as normal controls. 
 Isolation and Cell Culture of Human Fibroblasts 
 Primary fibroblasts were isolated from normal skin. Subcutane-
ous fat was removed from the respective tissue specimens and the 
remaining tissue was washed in phosphate-buffered saline. In order 
to isolate the dermis, specimens were incubated overnight at 4   °   C 
in sterile Dispase II (Roche) solution (4 mg/ml). The isolated der-
mis was minced into small pieces, and explants placed on culture 
dishes were overlaid with Dulbecco’s modified Eagle’s medium that 
was supplemented with 10% fetal bovine serum and penicillin 
(100 U/ml), and streptomycin (100 μg/ml; PAA Laboratories, Pas-
ching, Austria), and incubated at 37   °   C and 5% CO 2 . Skin-derived 
fibroblasts were grown in culture for 3–4 weeks and then passaged 
after trypsinization. Early passages of fibroblasts were seeded at a 
density of 3 × 10 4 cells into 12-well plates and switched to serum-
free medium at 70–80% confluence 24 h prior to exposure to IFN-γ 
(100 ng/ml; Biomol, Hamburg, Germany), psoriasin (S100A7) and 
koebnerisin (S100A15; 0.01–1 μg/ml) alone or in combination. 
 RNA Isolation and Quantitative Real-Time PCR 
 Cultured cells were harvested, and RNA was isolated using the 
RNA Miniprep Kit (Zymo Research, Irvine, Calif., USA). cDNA 
synthesis was performed with 1 μg of total RNA using the  DyNAmo 
cDNA Synthesis Kit (Finnzymes, Espo, Finland). Expression of 
COL1A1, COL1A2 und COL3A1, TGF-β 1 , -β 2 , -β 3 , fibronectin-1, 
laminin-β 2 and α-smooth-muscle actin were normalized against 
β-actin using commercial gene-specific primers (Qiagen, Hilden, 
Germany). Quantitative PCR (qPCR) assays were run in the 
CFX96 Real Time System as specified by the manufacturer (Bio-
Rad, Hercules, Calif., USA). All analyses were performed in tripli-
cate from 2 to 3 independent cell stimulation experiments. 
 Cell Viability and Proliferation Assays 
 Fibroblast viability was determined by crystal violet assay. Cells 
were exposed to koebnerisin (S100A15) and psoriasin (S100A7) 
alone or in combination for 24 h and then stained with crystal vio-
let (0.5 in 20% methanol) for 20 min at room temperature. Then, 
cells were decolorized with 0.1  M sodium citrate in 50% ethanol, 
and absorbance was read at 550 nm using a microplate reader 
(Spectra MR, Dynex Technology, Chantilly, Va., USA).
 Fibroblast proliferation was determined by the 5-bromo-2’-de-
oxyuridine (BrdU) Assay (Roche Applied Science, Mannheim, 
Germany) according to the manufacturer’s instructions. Cells 
were exposed to IFN-γ (100 ng/ml), koebnerisin (S100A15) and 
psoriasin (S100A7) alone or in combination for 48 h. At 24 h, BrdU 
labelling medium was added, and incoporated BrdU during cell 
proliferation was detected by an anti-BrdU horseradish peroxi-
dase-labelled antibody at 370 nm using a microplate reader (Spec-
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 Immunofluorescence Staining and Immunoblotting 
 Immunofluorescence staining was performed on serial 5-μm 
frozen sections of human normal and keloid skin and on primary 
fibroblasts derived from normal skin and keloids. Plated cells and 
skin sections were fixed in acetone and blocked in 10% normal goat 
serum. After overnight incubation with anti-S100A15 (5 μg/ml, 
customized), anti-S100A7 (1 μg/ml, Abcam, Cambridge, UK) and 
anti-vimentin (1: 50, Sigma Aldrich, Steinheim, Germany) anti-
body, sections and cells were then incubated with an Alexa Fluor 
647-labelled goat anti-rabbit antibody (Invitrogen, Carlsbad, Ca-
lif., USA) and with a tetramethylrhodamine-conjugated goat anti-
mouse antibody (Dianova, Hamburg ,  Germany) diluted in 10% 
normal goat serum and incubated for 1 h at room temperature in 
a dark humidified chamber. Staining with secondary antibodies 
only was performed as a control for unspecific antibody binding. 
Sections were overlaid with 4',6-diamidino-2-phenylindole (Pro-
Long Gold antifade reagent, Invitrogen). Images of fluorescent 
stained tissues were recorded using a 12-bit CCD digital camera 
PCO PixelFly (PCO, Kelheim, Germany) on a fluorescent micro-
scope Zeiss Imager Z1 (Zeiss, Jena, Germany). Immunoblotting 
was performed as previously described  [19] . In brief, skin or fibro-
blast lysates (15 μg/lane) were prepared using radioimmunopre-
cipitation assay buffer. Proteins were separated using a 12% sodi-
um dodecyl sulphate polyacrylamide gel, transferred to polyvinyl-
idene fluoride membranes, blocked and incubated with 
anti-hS100A15 (5 μg/ml, Costum), anti-S100A7 antibody (1 μg/
ml, Abcam) and anti-β-actin (1 μg/ml, Cell Signaling, Danvers, 
Mass., USA) overnight. After incubation for 1 h with horseradish 
peroxidase-conjugated secondary antibodies (anti-rabbit, Cell Sig-
naling; anti-mouse, Pierce), proteins were detected by chemolumi-
nescence. 
 Statistical Analysis 
 All statistical analyses were performed using GraphPad Prism 
4.0 (GraphPad Software Inc.). Student’s t test was used to calculate 
statistical differences. Values of p < 0.05 were considered signifi-
cant, and all data are displayed as means ± SD. 
 Results 
 Psoriasin (S100A7) and Koebnerisin (S100A15) Are 
Decreased in Keloid Tissue and Differently Produced 
by Normal and Keloid Fibroblasts  
 Our data showed that psoriasin (S100A7) and koeb-
nerisin (S100A15) are expressed in the upper differenti-
ated epidermal layers of normal skin ( fig. 1 A, a, c). Com-
pared to psoriasin, koebnerisin was also detectable at the 
epidermal-dermal junction. In keloid tissue sections, 
staining of either S100 protein was reduced within the epi-
dermis or underlying dermis ( fig. 1 A, b, d). We further 
identified normal fibroblasts as an additional cellular 
source for koebnerisin ( fig. 1 B, a, c). Koebnerisin was dis-
tributed throughout the cellular cytoplasm and partially 
colocalized with the mesenchymal marker vimentin. Ke-
loid-derived fibroblasts showed a similar expression pat-
tern, but stained more weakly for koebnerisin ( fig. 1 B, b, 
d), while psoriasin was not detectable in both normal and 
keloid-derived fibroblasts ( fig. 1 B, e, f). Immunoblot anal-
ysis in whole tissue showed psoriasin- and koebnerisin-
reactive bands in normal skin ( fig. 1 C). The psoriasin and 
koebnerisin protein expression varied among the individ-
ual skin tissue samples, but was overall weaker in keloid 
tissue when normalized to β-actin ( fig. 1 D). Thus, the co-
regulation of psoriasin and koebnerisin and their distri-
bution in different cellular compartments in the skin sug-
gest their functional contribution in keloid tissues. 
 Psoriasin (S100A7) and Koebnerisin (S100A15) Are 
Associated with Reduced Collagen Expression in the 
Skin and Inhibit Collagen Expression by Fibroblasts  
 Keloids form after prolonged inflammation that leads 
to an increased proliferation and activation of fibroblasts 
with enhanced deposition of disorganized collagen fibres 
of types 1 and 3 in the dermis  [20] . Whole tissue analysis 
demonstrated that COL1A1, COL1A2 and COL3A1 were 
produced in normal skin ( fig. 2 A). Skin biopsies from ke-
loid tissue showed an increased production of the inves-
tigated collagen types, which participate in fibrotic scar-
ring. In corresponding samples, both psoriasin (S100A7) 
and koebnerisin (S100A15) alternate transcripts 
(S100A15L and S100A15S) were present in normal skin. 
However, both S100 peptides were downregulated in the 
keloid tissue and revealed a reverse S100-collagen regula-
tion pattern under fibrotic conditions ( fig. 2 B, compare 
 fig. 1 ). Data implied that psoriasin and koebnerisin affect 
collagen production in fibroblasts. Cultured fibroblasts 
were then exposed to increasing S100 peptide concentra-
tions, and their effect on collagen expression was mea-
sured. Data showed that recombinant psoriasin de-
creased expression of COL1A1, COL1A2 and COL3A1 at 
various concentrations and significantly reduced levels of 
 COL3A1 compared to controls ( fig. 2 C). Also, recombi-
nant koebnerisin significantly decreased expression of 
COL1A1 and COL3A1 at most of the concentrations uti-
lized ( fig. 2 D). Exposure of cultured fibroblasts to psoria-
sin and koebnerisin at effective collagen-suppressing 
concentration did not influence the number of viable cells 
as determined by the crystal violet assay (data not shown). 
 Psoriasin (S100A7) and Koebnerisin (S100A15) 
Synergize to Attenuate Expression of ECM Proteins by 
Fibroblasts 
 Psoriasin (S100A7) and koebnerisin (S100A15) are co-
regulated under pathological conditions and show syner-
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both peptides individually regulate collagen expression in 
fibroblasts ( fig. 2 C, D), their synergistic effect on fibroblast 
activity was investigated. When used in combination, the 
suppressing effect of psoriasin and koebnerisin on fibro-
blast activity was  further enhanced for all investigated col-
lagen types ( COL1A1, COL1A2, COL3A1;  fig. 3 A). Next, 
cultured fibroblasts were exposed to psoriasin and koeb-
nerisin peptides at concentrations that were effective to 
suppress the regulation of collagens. Data showed that each 
recombinant psoriasin and koebnerisin peptide decreased 
the expression of fibronectin in fibroblasts ( fig. 3 B). Their 
suppressing effect was further enhanced when both pep-
tides were used in combination and was more effective than 
IFN-γ (positive control,  fig. 3 B). The combination of pso-
riasin and koebnerisin also significantly inhibited the ex-
pression of laminin-β 2 and α-smooth-muscle actin in fi-
broblasts ( fig. 3 C, D). Cultured fibroblasts exposed to ei-
ther recombinant psoriasin or koebnerisin peptides 
slightly affected the expression of TGF-β 1 , -β 2 and -β 3 , 
where koebnerisin had the most pronounced effect on 
TGF-β 3 ( fig. 3 E). When used in combination, psoriasin and 
koebnerisin significantly reduced expression of all investi-
gated TGF-β isoforms. Compared to the S100 peptides, 
IFN-γ suppressed the expression of TGF-β 2 and -β 3 in cul-
tured fibroblasts, but did not regulate TGF-β 1 expression.
 Psoriasin (S100A7) and Koebnerisin (S100A15) 
Synergize to Suppress Fibroblast Proliferation  
 To gain insight into other antifibrotic effects of the S100 
peptides, we investigated the functional importance of 
 Fig. 1. Psoriasin (S100A7) and koebnerisin (S100A15) expression 
and distribution in keloid tissue and keloid fibroblasts.  A Frozen 
skin tissue sections from normal subjects ( a ,  c ) and patients with 
keloids ( b ,  d ) immunostained for psoriasin (S100A7) and koeb-
nerisin (S100A15). Scale bar = 100 μm.  B Cultured fibroblasts iso-
lated from normal skin ( a ,  c ,  e ) and keloid biopsies ( b ,  c ,  f ) immu-
nostained for vimentin, psoriasin and koebnerisin. Scale bar = 100 
μm.  C Total protein lysates of normal skin and keloid scar tissue 
(15 μg/lane) were probed with specific antibodies against psoriasin 
and koebnerisin.  D Psoriasin and koebnerisin staining intensities 











































































   
   
   
   
   
   
   
   
   
   
   





























































































































































































































































































































 Fig. 2. Psoriasin (S100A7) and koebnerisin (S100A15) mark de-
creased collagen expression in the skin and inhibit collagen expres-
sion by fibroblasts. Total RNA was extracted from biopsies of nor-
mal skin (n = 9) and keloid scar tissue (n = 9), and real-time qPCR 
was performed to assay collagen types 1 and 3 (COL1A1, COL1A2, 
COL3A1;  A ) and psoriasin (S100A7) and koebnerisin (S100A15-S, 
S100A15-L) transcripts ( B ) using gene-specific primers. Cultured 
fibroblasts were treated with indicated concentrations of psoriasin 
(S100A7;  C ) and koebnerisin (S100A15;  D ), and collagen type 1 
and 3 expression was analysed by real-time qPCR.  *  p < 0.05 de-
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psoriasin (S100A7) and koebnerisin (S100A15) on fibro-
blast proliferation. Cultured fibroblasts were exposed to 
psoriasin and koebnerisin peptides at concentrations that 
were effective to suppress the expression of ECM compo-
nents. Each recombinant psoriasin and koebnerisin pep-
tide significantly inhibited the proliferation of fibroblasts 
as measured by reduced BrdU uptake (data not shown). 
The antiproliferative effect was further enhanced when 
both S100 peptides were used in combination ( fig. 3 F). In 
contrast, incubation of fibroblasts with IFN-γ increased 
BrdU uptake, which is indicative of a stimulation of fibro-
blast proliferation.
 Fig. 3. Psoriasin (S100A7) and koebnerisin (S100A15) synergize to 
suppress ECM expression by fibroblasts and inhibit fibroblast pro-
liferation.  A–F Cultured fibroblasts were treated with IFN-γ 
(0.1 μg/ml), psoriasin (S100A7) and koebnerisin (S100A15) alone 
or in combination. Total RNA was extracted, and real-time qPCR 
was performed to assay collagen types 1 and 3 (COL1A1, COL1A2, 
COL3A1;  A ), fibronectin-1 ( B ), laminin-β 1 ( C ), α-smooth-muscle 
actin ( D ) and TGF-β types 1–3 ( E ) using gene-specific primers. 
 F  Proliferation of cultured fibroblasts was analysed by BrdU incor-
















































































































































































   
   
   
   
   
   
   
   
   
   
   

























 Transformation of a wound clot into granulation tis-
sue requires a delicate balance between ECM protein de-
position and degradation, and when disrupted, abnor-
malities in scarring appear  [1] . Despite a plethora of in 
vivo and in vitro studies investigating the complex mech-
anisms underlying hypertrophic scar formation, its 
pathophysiology remains poorly understood. Diverse 
proteins have been suggested to be involved in excessive 
scar formation; however, to date, little attention has been 
paid to the S100 proteins.
 Genes of the S100 family encode small (9–13 kDa), cal-
cium-binding proteins of the EF hand type that regulate 
tissue maturation, inflammation and antimicrobial de-
fence  [12] . Dysregulated levels of certain S100 peptides 
have previously been detected during wound repair of 
epithelia and other tissues  [14–16, 23] . Upregulated in the 
hyperproliferative epidermis, S100A8 and S100A9 pro-
mote the growth of epithelial keratinocytes  [24–26] , 
whereas S100A2 drives TGF-β-dependent mesenchymal 
cell migration  [20] . S100B mediates myofibroblast prolif-
eration and might contribute to the scar formation ob-
served in the infarcted myocardium  [27] . Increased fibro-
blast activation and chronic fibrotic kidney disease have 
been associated with S100A4, which has been established 
as a diagnostic marker for systemic fibrotic disorders 
 [28] . 
 In this context, we aimed to elucidate the signifi-
cance of two S100 proteins, psoriasin (S100A7) and 
koebnerisin (S100A15), for the pathogenesis of keloid 
formation.
 Psoriasin and koebnerisin form a unique subgroup 
of the S100 protein family and were discovered to be up-
regulated in psoriatic skin  [17, 29] . Although being 
highly homologous peptides, psoriasin and koebnerisin 
have distinct functions as epidermal antimicrobial pep-
tides, leucocyte attractants and pro-inflammatory 
‘alarmins’  [18] . Compared with psoriasin, koebnerisin 
is also expressed by additional cell types in the skin, 
such as endothelial cells and smooth muscle cells. Here, 
we noticed a predominent interface pattern ( fig.  1 A), 
which may also be due to the fact that staining intensity 
varies among the different cell types and depends on the 
imaging conditions. We also discovered that skin fibro-
blasts serve as another source of koebnerisin ( fig. 1 B). 
Interestingly, when compared to normal skin, staining 
of keloid tissue sections for both S100 proteins was sig-
nificantly reduced within the epidermis and underlying 
dermis. 
 Both koebnerisin mRNA isoforms lead to the same 
protein and were expressed in normal fibroblasts, but 
were downregulated in keloid-derived fibroblasts. Pso-
riasin transcript, however, could not be detected in ei-
ther type of fibroblasts. Whole tissue immunoblot anal-
ysis further demonstrated that psoriasin and koebneri-
sin staining intensity was overall weaker in keloid tissue 
when compared with normal skin ( fig. 1 ). 
 Recent evidence suggests that the type of immune re-
sponse predisposes to excessive scarring  [5] . While the 
development of a Th2 response has been strongly linked 
to fibrogenesis, a predominance of Th1 CD41 cells has 
been shown to almost completely attenuate the formation 
of tissue fibrosis via production of IFN-γ  [6, 7] . Both pso-
riasin and koebnerisin are inducible by Th1-derived cy-
tokines in epidermal keratinocytes  [11, 30] , and the lack 
of inducibility of both S100 by Th2-derived cytokines 
may account for the low expression levels of psoriasin and 
koebnerisin in keloid tissue  [31] . 
 Importantly, low S100 protein expression correspond-
ed to high levels of profibrotic markers, such as collagens, 
in keloid tissue ( fig. 2 A, B). This data suggests that sub-
epidermal fibroblasts in keloid tissue might be exposed to 
decreased levels of secreted psoriasin and koebnerisin 
that, in turn, could affect the production of collagens and 
other extracellular matrix compounds. 
 In fact, when fibroblasts were exposed to either S100 
peptide, the expression of both collagen types 1 and 3 was 
attenuated ( fig. 2 C, D;  fig. 3 A). Also, both psoriasin and 
koebnerisin peptides individually decreased the expres-
sion of other ECM compounds, such as fibronectin-1, 
laminin-β 2 and α-smooth-muscle actin, without affect-
ing fibroblast viability. The suppressing patterns of pso-
riasin and koebnerisin on the ECM components were 
different and are in line with distinct functional mecha-
nisms of these S100 peptides. Despite their high homol-
ogy, extracellular psoriasin and koebnerisin activate dif-
ferent classes of receptors  [21] . Psoriasin activates the 
pattern recognition receptor ‘receptor of advanced gly-
cated end products’, whereas koebnerisin functions 
through a pertussis toxin-sensitive Gi protein-coupled 
receptor. When coregulated under pathophysiological 
conditions, both S100 peptides can exert synergistic ef-
fects. Here, we could show that co-exposure of fibro-
blasts to psoriasin and koebnerisin leads to a synergistic 
inhibition of the ECM components ( fig. 3 ). In some in-
stances, their combined effect was comparable to that of 
IFN-γ, which has previously been established as one of 
the most potent inhibitors of ECM-related genes, such as 
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 TGF-β signalling has been implicated as key regulator in 
early stages of ECM production and in keloid formation. 
While TGF-β 1 and -β 2 represent the most important stim-
ulators of collagen and proteoglycan synthesis  [35, 36] , 
TGF-β 3 reduces connective tissue deposition  [37] . We 
could demonstrate that the combination of psoriasin and 
koebnerisin significantly attenuated the expression of 
TGF-β subtypes 1–3; however, the suppressive effects of 
IFN-γ on TGF-β 2 and -β 3 were much more pronounced. 
Nevertheless, incubation of cultured fibroblasts with pso-
riasin and koebnerisin did significantly attenuate fibroblast 
proliferation, which could account for the suppressive ef-
fects of psoriasin (S100A7) and koebnerisin (S100A15) on 
ECM production. Thus, although the exact molecular 
mechanism underlying the S100 antifibrotic effects re-
mains currently unclear, a better understanding of these 
two proteins may give additional insights into the complex 
pathophysiology of fibroproliferative diseases of the skin.
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